PRF Technologies is no longer the single-asset post-surgical pain company that missed its late-2024 Phase Three primary endpoint. The Israeli issuer spent the following year buying an AI solar analytics platform, taking a majority stake in a Boston ocular-delivery company, changing its legal name, and executing a reverse split. The first half then put cash and a new lead program on the page. The April clearance of the investigational new drug application for OcuRing-K is the healthcare event that now carries the residual claim. The May equity-line draw that lifted cash to roughly twelve million is the financing event that keeps operations funded.
The strategic tension is that the cash rebuild was purchased with a share-count explosion and a listing-value problem. Ordinary shares outstanding more than tripled between year-end and period-end, and a further several hundred thousand shares were sold after the balance-sheet date. Market value of listed securities sat near $3 million in early September. That figure sits below the proposed $5 million Nasdaq floor. DeepSolar booked its first revenue. The solar segment still lost more than $1 million at the operating line.
The next several months resolve whether OcuRing-K actually enrolls a United States Phase Two cataract study and whether DeepSolar's named counterparties convert pilots into recurring software fees large enough to matter. Management states the cash covers at least twelve months from the issuance date of the interim statements. The equity still trades at a fraction of cash per share, which is the market's verdict on dilution, listing risk, and an unfinished clinical restart.